^
Association details:
| Biomarker: | KRAS mutation + SMARCA4 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical characteristics, co-mutations and outcomes of advanced non-small cell lung cancer (NSCLC) patients with KRAS mutations.
Published date:
05/19/2021
Excerpt:
KRAS+/SMARCA4+ had worse PFS (1.0 vs 6.9 m, p < 0.0001) and OS (1.4 vs. 27.8, p = 0.0001) compared to KRAS+/SMARCA4wt....Our data shows that pts with KRAS co-mt with STK11/KEAP1 had worse PFS and OS with the addition of immunotherapy compared to chemotherapy alone, highlighting the potential implications of these co-mt patterns on treatment outcomes.
DOI:
10.1200/JCO.2021.39.15_suppl.e21174
Source:
Title:
SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition
Published date:
04/09/2021
Excerpt:
The deleterious effect on immunotherapy outcomes in KRAS-mutant NSCLC was most pronounced in the SMARCA4-mutant subset (N=17), with a lower ORR (22% vs 0%, P=0.03) a significantly shorter mPFS (4.1 vs 1.4 months; HR: 0.25 [95%CI: 0.14-0.42]; P<0.001), and a significantly shorter mOS (15.1 vs 3.0 months; HR: 0.29 [95%CI: 0.17-0.50]; P<0.001) compared to SMARCA4-wt KRAS-mutant NSCLCs.
DOI:
10.1016/j.jtho.2021.03.024
Source:
Title:
Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).
Published date:
05/13/2020
Excerpt:
Among 513 patients with nonsquamous NSCLC who received immune checkpoint inhibitors...among KRASmut NSCLC, a concurrent SMARCA4 mut conferred a significantly lower ORR (23.1% vs 0.0%; P = 0.02), a significantly shorter mPFS (4.8 months vs 1.7 month; HR: 0.31 [95% CI: 0.15-0.61]; P < 0.001), and a significantly shorter mOS (15.6 months vs 2.7 months; HR: 0.25 [95%CI: 0.12-0.49]; P < 0.001).
DOI:
10.1200/JCO.2020.38.15_suppl.9577
